ArticleJCEM case reports2026
Episodic hypercortisolemia-mediated periods of worsening hyperglycemia in cyclic Cushing syndrome.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic Cushing syndrome (CCS) is a rare subtype of Cushing syndrome (CS) characterized by hypercortisolism alternating with periods of physiologic or even low cortisol secretion. Most patients with CCS present with clinical signs of CS; however, in some patients, signs of hypercortisolism may be subtle or even absent. The fluctuating clinical picture and discrepant biochemical findings make CCS difficult to diagnose. We describe a case of a 70-year-old man with well-controlled type 2 diabetes mellitus who experienced recurrent, spontaneous hypercortisolemic episodes resulting in worsening and difficult-to-control hyperglycemia, followed by eucortisolemic phases during which his glycemic control rapidly returned to baseline. Further biochemical evaluation revealed intermittent hypercortisolemia without a clearly identifiable source of an adrenocorticotropic hormone secreting lesion. Data from his continuous glucose monitoring system (CGMS) proved pivotal in detecting the hypercortisolemic phases and tailoring management. After declining bilateral adrenalectomy and opting for a block-and-replace regimen with osilodrostat and hydrocortisone, he was able to anticipate and initiate this treatment based on his CGMS readings, facilitating improved glycemic control during these periods. This case highlights the diagnostic complexity of CCS and the utility of CGMS as both a monitoring tool and treatment guide for CCS in patients with concurrent type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.